| Overview |
| bsm-70036M |
| CDK5 Antibody |
| WB, IHC |
| Specific for endogenous levels of the ~28 kDa Cdk5 protein. Shows no cross reactivity with the Cdk5 cofactor p35 or its degradation product p25. |
| Human, Mouse, Rat |
| Specifications |
| Unconjugated |
| Mouse |
| Purified rat Cdk5. |
| Monoclonal |
| 1H3 |
| IgG1 |
| Lot Dependent |
| Purified by Protein G. |
| 10 mM HEPES (pH 7.5), 150 mM NaCl, 100 µg per ml BSA and 50% glycerol. |
| Storage at -20°C is recommended, as aliquots may be taken without freeze/thawing due to presence of 50% glycerol. Stable for at least 1 year at -20°C. |
| Target |
| 140908 |
| Q03114 |
| Cdk 5 antibody, Cdk5 antibody, CDK5_HUMAN antibody, Cell division protein kinase 5 antibody, Crk6 antibody, Cyclin dependent kinase 5 antibody, Cyclin-dependent kinase 5 antibody, Protein kinase CDK5 splicing antibody, PSSALRE antibody, Serine threonine protein kinase PSSALRE antibody, Serine/threonine-protein kinase PSSALRE antibody, Tau protein kinase II catalytic subunit antibody, TPKII catalytic subunit antibody |
| The neuronal protein kinase, Cdk5 has been implicated in a vast array of normal neuronal functions including regulation of neurotransmitter synthesis (Kansy J et al., 2004), the presynaptic vesicle cycle (Nguyen, C. & Bibb, JA 2003), neurotransmitter receptor trafficking and dopamine neurotransmission (Bibb, JA et al. 1999). At the same time Cdk5 has been implicated in a plethora of neurological and neuropsychiatric disorders including Alzheimer’s, Parkinson’s, Huntington’s, epilepsy, schizophrenia, and drug addiction. Detection of Cdk5 in normal samples as well as tissue undergoing neurodegeneration may advance studies in these areas. Moreover, this antibody may allow more accurate postmortem evaluations of Cdk5 protein expression, and thus serve as a valuable new reagent for neuropathology. |
| Application Dilution |
| WB |
1:300-5000 |
| IHC |
|
Powered by Bioz